These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31924650)

  • 21. Exploring of primate models of tick-borne flaviviruses infection for evaluation of vaccines and drugs efficacy.
    Pripuzova NS; Gmyl LV; Romanova LIu; Tereshkina NV; Rogova YV; Terekhina LL; Kozlovskaya LI; Vorovitch MF; Grishina KG; Timofeev AV; Karganova GG
    PLoS One; 2013; 8(4):e61094. PubMed ID: 23585873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protection against European isolates of tick-borne encephalitis virus after vaccination with a new tick-borne encephalitis vaccine.
    Klockmann U; Krivanec K; Stephenson JR; Hilfenhaus J
    Vaccine; 1991 Mar; 9(3):210-2. PubMed ID: 2042394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of rapid scheme vaccination against tick-borne encephalitis in HIV-1 infected persons.
    Jilich D; Maly M; Kosina P; Fleischhans L; Machala L
    Epidemiol Infect; 2021 Jan; 149():e41. PubMed ID: 33504405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humoral immunity against tick-borne encephalitis virus following manifest disease and active immunization.
    Klockmann U; Bock HL; Kwasny H; Praus M; Cihlová V; Tomková E; Krivanec K
    Vaccine; 1991 Jan; 9(1):42-6. PubMed ID: 2008800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid vaccination protocols for commercial vaccines against tick-borne encephalitis.
    Stephenson JR; Lee JM; Easterbrook LM; Timofeev AV; Elbert LB
    Vaccine; 1995; 13(8):743-6. PubMed ID: 7483789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetics of the immune response after primary and booster immunization against tick-borne encephalitis (TBE) in adults using the rapid immunization schedule.
    Zent O; Jilg W; Plentz A; Schwarz TF; Frühwein N; Kuhr HB; Banzhoff A
    Vaccine; 2003 Dec; 21(32):4655-60. PubMed ID: 14585672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of the efficiency of tick-borne encephalitis vaccination in the population in the natural foci of Austria].
    Heinz F; Holtzmann H; Essl A; Kundt M
    Vopr Virusol; 2008; 53(2):19-27. PubMed ID: 18450105
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination against tick-borne encephalitis (TBE): influence of simultaneous application of TBE immunoglobulin on seroconversion and rate of adverse events.
    von Hedenström M; Heberle U; Theobald K
    Vaccine; 1995; 13(8):759-62. PubMed ID: 7483792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficiency of coadministration of immunomodulators and vaccine in an experiment on tick-borne encephalitis].
    Barinskiĭ IF; Lazarenko AA; Alimbarova LM; Davydova AA
    Vopr Virusol; 2011; 56(4):45-7. PubMed ID: 21899071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and testing of a new tick-borne encephalitis virus vaccine candidate for veterinary use.
    Salát J; Formanová P; Huňady M; Eyer L; Palus M; Ruzek D
    Vaccine; 2018 Nov; 36(48):7257-7261. PubMed ID: 30337175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis.
    Stiasny K; Aberle JH; Keller M; Grubeck-Loebenstein B; Heinz FX
    PLoS One; 2012; 7(3):e34145. PubMed ID: 22461903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second five-year follow-up after a booster vaccination against tick-borne encephalitis following different primary vaccination schedules demonstrates at least 10 years antibody persistence.
    Beran J; Lattanzi M; Xie F; Moraschini L; Galgani I
    Vaccine; 2019 Jul; 37(32):4623-4629. PubMed ID: 29397225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An accelerated schedule for tick-borne encephalitis vaccine: the American Military experience in Bosnia.
    Craig SC; Pittman PR; Lewis TE; Rossi CA; Henchal EA; Kuschner RA; Martinez C; Kohlhase KF; Cuthie JC; Welch GE; Sanchez JL
    Am J Trop Med Hyg; 1999 Dec; 61(6):874-8. PubMed ID: 10674662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcome and cerebrospinal fluid profiles in patients with tick-borne encephalitis and prior vaccination history.
    Lenhard T; Ott D; Jakob NJ; Martinez-Torres F; Grond-Ginsbach C; Meyding-Lamadé U
    Ticks Tick Borne Dis; 2018 May; 9(4):882-888. PubMed ID: 29576392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence of immunity to tick-borne encephalitis after vaccination and natural infection.
    Baldovin T; Mel R; Bertoncello C; Carpenè G; Soppelsa F; Giliberti A; Baldo V
    J Med Virol; 2012 Aug; 84(8):1274-8. PubMed ID: 22711356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ability of inactivated vaccines based on far-eastern tick-borne encephalitis virus strains to induce humoral immune response in originally seropositive and seronegative recipients.
    Maikova GB; Chernokhaeva LL; Rogova YV; Kozlovskaya LI; Kholodilov IS; Romanenko VV; Esyunina MS; Ankudinova AA; Kilyachina AS; Vorovitch MF; Karganova GG
    J Med Virol; 2019 Feb; 91(2):190-200. PubMed ID: 30204244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A comparison of the immune response induced by DNA or by an inactivated vaccine against tick-borne encephalitis].
    Morozova OV; Popova RV; Maksimova TG; Mitrofanova EE; Bakhvalova VN
    Zh Mikrobiol Epidemiol Immunobiol; 2000; (2):54-7. PubMed ID: 10808575
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized phase II study of a new tick-borne encephalitis vaccine using three different doses and two immunization regimens.
    Harabacz I; Bock H; Jüngst C; Klockmann U; Praus M; Weber R
    Vaccine; 1992; 10(3):145-50. PubMed ID: 1557929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 3 immunogenicity and safety study of a tick-borne encephalitis vaccine in healthy Japanese participants 1 year of age and older.
    Yonekawa M; Watanabe T; Kogawara O; Yoshii C; Yamaji M; Aizawa M; Erber W; Ito S; Jug B; Koelch D; de Solom R; Lockhart SP
    Vaccine; 2024 May; 42(13):3180-3189. PubMed ID: 38614954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can the booster interval for the tick-borne encephalitis (TBE) vaccine 'FSME-IMMUN' be prolonged? - A systematic review.
    Steffen R; Erber W; Schmitt HJ
    Ticks Tick Borne Dis; 2021 Sep; 12(5):101779. PubMed ID: 34298356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.